HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women.

AbstractPURPOSE:
Human papillomavirus (HPV) is the causative agent of cervical cancer. Black women are disproportionally diagnosed and have higher mortality from cervical cancer in the United States. Here we describe the prophylactic efficacy and safety of a quadrivalent HPV-6/11/16/18 vaccine in black women.
METHODS:
A total of 700 black women from Latin America, Europe, and North America (aged 16-24 years) received the vaccine or placebo in one of two studies. Analyses focused on the efficacy and safety of the vaccine.
RESULTS:
Baseline rates of Chlamydia trachomatis infection and history of past pregnancy were more than twice as high in black women compared with the non-black women who were enrolled in these trials. HPV-6/11/16 or 18 DNA was detected in 18% of black women versus 14.6% in non-black women at day 1. For black women, vaccine efficacy against disease caused by HPV-6/11/16/18 was 100% for cervical intraepithelial neoplasia (0 vs. 15 cases; 95% confidence interval, 64.5%-100%) and 100% for vulvar and vaginal intraepithelial neoplasia and condylomata acuminata (0 vs. 17 cases; 95% confidence interval, 69.3%-100%). There were no serious vaccine-related adverse experiences. A similar proportion of pregnancies resulted in live births (75.8% vaccine; 72.7% placebo) and fetal loss (24.2% vaccine; 27.3% placebo).
CONCLUSIONS:
Prophylactic quadrivalent HPV-6/11/16/18 vaccination of young black women demonstrated high efficacy, safety, and tolerability. HPV vaccination has the potential to reduce cervical cancer-related health disparities both in the United States and around the world.
AuthorsLiana R Clark, Evan R Myers, Warner Huh, Elmar A Joura, Jorma Paavonen, Gonzalo Perez, Margaret K James, Heather L Sings, Richard M Haupt, Alfred J Saah, Elizabeth I O Garner
JournalThe Journal of adolescent health : official publication of the Society for Adolescent Medicine (J Adolesc Health) Vol. 52 Issue 3 Pg. 322-9 (Mar 2013) ISSN: 1879-1972 [Electronic] United States
PMID23299013 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 Society for Adolescent Health and Medicine. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Papillomavirus Vaccines
Topics
  • Adolescent
  • Black or African American
  • Alphapapillomavirus
  • Black People
  • Chlamydia Infections (epidemiology)
  • Chlamydia trachomatis (isolation & purification)
  • Female
  • Human papillomavirus 11
  • Humans
  • Papilloma (prevention & control)
  • Papillomavirus Infections (epidemiology, prevention & control)
  • Papillomavirus Vaccines (therapeutic use)
  • United States (epidemiology)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: